The development of a successful vaccine is a significant undertaking that takes years to achieve. The Sabin Vaccine Institute Product Development Partnership (PDP) is internationally recognized for its development of safe, effective vaccines against tropical infections including human hookworm, schistosomiasis, Chagas disease, leishmaniasis and SARS. Sabin PDP esteemed partners include:

Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development at Baylor College of Medicine 
Houston, Texas, USA
The Center for Vaccine Development houses the product development laboratories of the PDP and specifically works on the selection, screening and feasibility of expression platforms for vaccine candidates. In addition it has capabilities for recombinant protein process development to guide technology transfer, training and capacity building for current Good Manufacturing Practice (cGMP) production of vaccine candidates. The portfolio of vaccine programs includes hookworm, schistosomiasis, Chagas, leishmaniasis and SARS.

The George Washington University (GW) - Department of Microbiology, Immunology and Tropical Medicine
Washington, DC, USA
For the hookworm and schistosomiasis vaccine programs, GW leads the clinical testing in collaboration with the Brazilian partners. Under the HOOKVAC consortium, GW plays an integral role in designing the clinical trials and serves in an advisory position throughout trials in Gabon. Laboratory and field work includes preclinical immunological assessment, vaccine potency testing and assessment of human immune responses to the vaccine antigens.

University of Kansas
Lawrence, Kansas, USA
The University of Kansas collaborates with the product development laboratories in Houston to assess the vaccine candidates’ preformulation studies, biophysical characterization and the high throughput screening of GRAS (Generally Regarded as Safe) reagents to be used as potential vaccine stabilizers.

Fundacao Oswaldo Cruz (FIOCRUZ)
Belo Horizonte, Minas Gerais, Brazil
FIOCRUZ, the research arm of the Brazilian ministry of health, serves as the center for epidemiological assessments and provides the clinical testing sites in Brazil, including a field clinic and laboratory specifically for the hookworm and schistosomiasis programs. In addition, Biomanguinhos, FIOCRUZ is the public sector vaccine manufacturer that will serve as the Brazilian manufacturing partner for technology transfer, scale-up process development and clinical grade manufacture of the hookworm vaccine.

James Cook University (JCU)
Brisbane, Queensland, Australia
JCU performs research and development activities primarily for target candidate discovery, early evaluation, characterization and ranking for hookworm and schistosomiasis programs.

London School of Hygiene and Tropical Medicine (LSHTM)
London, England
LSHTM designs and conducts statistical analysis for the clinical trials in Brazil. They also conduct mathematical modeling and cost-effectiveness analysis which have informed our global access strategy including vaccine development, introduction, distribution and financing.

Instituto Butantan
Sao Paulo, Brazil
Insituto Butantan is a public sector vaccine manufacturer in Sao Paulo, Brazil, and that serves as the Brazilian manufacturing partner for technology transfer, scale-up process development and clinical grade manufacture of the schistosomiasis vaccines.

The Institute of Parasite Diseases, Chinese Centers for Disease Control and Prevention
Beijing, China
IPD carries out research and preclinical testing of the hookworm vaccine candidates by utilizing an adapted hamster model against the human hookworm Necator americanus.

Autonomous University of Yucatan (UADY)
Yucatán, Mexico
UADY handles preclinical work for Sabin’s Chagas disease and leishmaniasis programs. This work includes assessment of immunogenicity and efficacy of these vaccines candidates.

Center for Research and Advanced Studies of the National Polytechnic Institute (CINESTAV)
Mexico City, Mexico
CINVESTAV, in collaboration with the product development laboratories in Houston, is building its capacity and learning how to perform process development and scale up of recombinant protein vaccine candidates. 

BIRMEX
Mexico City, Mexico
Birmex is Mexico’s leading public sector vaccine manufacturer and serves as the Mexican manufacturing partner for technology transfer, scale-up process development and clinical grade manufacture of the Chagas and Leishmaniasis vaccines.

National Institutes of Health (NIH), Laboratory of Malaria and Vector Research, Vector Molecular Biology Section
Bethesda, Maryland, USA
These laboratories handle preclinical work for the leishmaniasis vaccine program. This work includes assessment of immunogenicity and efficacy of these vaccines candidates.

New York Blood Center
New York, New York, USA
The New York Blood Center handles preclinical work for the Sabin PDP SARS vaccine program.  This work includes assessment of immunogenicity of the vaccine candidates.

University of Texas Medical Branch (UTMB)
Galveston, Texas, USA
UTMB handles preclinical work for the Sabin PDP SARS vaccine program.  This work includes assessment of immunogenicity efficacy of the vaccine candidates.

UNIVERSITY OF NOTTINGHAM
Nottingham, United Kingdom
The University of Nottingham collaborates with the Sabin PDP on the development of the human hookworm vaccine.  University of Nottingham has experience with experimental hookworm challenge infection studies and is advising the PDP on adapting this model for proof-of-concept testing of the hookworm vaccine.  In addition, the University will supply the GMP-grade hookworm larvae that will be used in the Sabin PDP's hookworm challenge studies.

AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT (AIGHD)
Amsterdam, The Netherlands
AIGHD provides the overall project management for the HOOKVAC Consortium. Under this consortium, the human hookworm vaccine is beginning clinical testing in sub-Saharan Africa and the two antigens under development, Na-GST-1 and Na-APR-1, will be combined into a single bivalent vaccine.

ACADEMIC MEDICAL CENTER, UNIVERSITY OF AMSTERDAM (AMC)
Amsterdam, The Netherlands
AMC primarily oversees the clinical trials of the hookworm vaccine in adults and children in Lambaréne, Gabon. This work is conducted in close collaboration with Hôpital Albert Schweitzer in Gabon.

LEIDEN UNIVERSITY MEDICAL CENTER (LUMC)
Leiden, Netherlands
LUMC leads the testing of the human hookworm vaccine’s mode of action. This work is useful in understanding the prophylactic mechanism the vaccine elicits.

Q-BIOLOGICALS
Zwijnaarde, Belgium
Q-Biologicals is a small- to medium-sized enterprise (SME) in the HOOKVAC consortium. Q-Biologicals works on the process development, assay development and manufacture of the human hookworm vaccine.

UNIVERSITY OF TUEBINGEN
Tuebingen, Germany
University of Tuebingen has expanded on its long-standing partnership with the LUMC under the HOOKVAC consortium.  The University of Tuebingen serves an advisory role for the clinical trials for the hookworm vaccine in Gabon.

PHARMIDEX PHARMACEUTICAL SERVICES LIMITED
London, United Kingdom
Pharmidex, a European SME under the HOOKVAC Consortium, is responsible for formulation and toxicology for the bivalent hookworm vaccine.

HÔPITAL ALBERT SCHWEITZER
Lambaréne, Gabon
Hôpital Albert Schweitzer leads the clinical testing of the human hookworm vaccine in
Lambaréne, Gabon. This testing includes studies in both adults and children as part of the HOOKVAC project.